Know Cancer

forgot password

A Pilot Study in Cancer Patients With Central Venous Catheter Associated Deep Vein Thrombosis in the Upper Extremity Treated With Rivaroxaban (Catheter 2)

Phase 4
18 Years
Not Enrolling
Neoplasm, Central Venous Catheter Thrombosis

Thank you

Trial Information

A Pilot Study in Cancer Patients With Central Venous Catheter Associated Deep Vein Thrombosis in the Upper Extremity Treated With Rivaroxaban (Catheter 2)

This will be a prospective cohort study of patients who present with an acute upper limb
thrombosis in the setting of a central venous catheter. The total study duration will be 12
weeks, with one follow up telephone visit at 6 months. All patients will be treated with
rivaroxaban at a dose of 15 mg orally twice daily for three weeks, followed by 20 mg daily.
Anticoagulation will continue for three months regardless of the length of time the catheter
is in place. Continuation of anticoagulation beyond this time period is at the discretion of
the investigators.

Strengths of this study include its prospective cohort format, and access to a large
oncologic population through the London Regional Cancer Program and other corresponding
centres. In addition, The Catheter Study looking at CVC survival and safety in patients with
cancer diagnosed with UEDVT and treated with a bridging protocol of warfarin/dalteparin was
organized primarily through the LHSc and results therein could be directly compared to the
results from this study given the similar patient population.

Limitations of this study include the small sample size and the fact that there is no LMWH
monotherapy comparison group. In addition, this will be an open study with no blinding,
given the nature of line survival. There is also the chance that a proportion of patients
will have their catheters removed for other reasons, such as finishing treatment or personal
preference, which could affect the validity of survival results.

This design was selected given the small number of patients presenting with this diagnosis
each year at our centre, which would present difficulty in accruing enough patients for
several comparisons group. Results will be compared to the Catheter Study and previous

Inclusion Criteria:

1. Male or female > 18 years of age.

2. Symptomatic acute upper limb thrombosis in the axillary, subclavian, innominate or
internal jugular veins, with or without pulmonary embolism, associated with central
venous catheter objectively documented by compression ultrasonography, venogram or CT

3. Diagnosis of active malignancy (other than non-melanoma skin cancer), defined as
patients who are either receiving active treatment, or have metastatic disease or who
have been diagnosed within the past two years.

4. Willing to provide written informed consent.

Exclusion Criteria:

1. Dialysis catheters.

2. Active bleeding or high risk for major bleeding.

3. Platelet Count < 75 x 109/L.

4. Creatinine Clearance < 30 mL/min.

5. Currently on other anticoagulant with therapeutic intent for another indication.*

6. Pulmonary embolism accompanied by hemodynamic instability or oxygen requirement.

7. Inability to infuse through the catheter after a trial of intraluminal thrombolytic
therapy (ie. 2 mg tPA).

8. Patients with AML, ALL or multiple myeloma with a bone marrow or stem cell transplant
planned within the next 3 months.

9. Thrombosis involving the brachial or cephalic veins only.

10. Treatment for current episode > 7 days with any acceptable anticoagulant therapy.

11. Concomitant use of P-glycoprotein and CYP3A4 inhibitors (ie. azole antifungals such
as ketoconazole) or inducers (ie. rifampicin, antiepileptics).*

12. Recent coronary artery stent requiring dual anti-platelet therapy.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Proportion of central line failure, defined as infusion failure that does not respond to 2mg tPA.

Outcome Description:

The primary endpoint of the study will be proportion of central line failure, defined as infusion failure that does not respond to 2mg tPA, within the 3 months of study follow-up.

Outcome Time Frame:

12 weeks

Safety Issue:


Principal Investigator

Dr. Michael J. Kovacs, MD, FRCPC

Investigator Role:

Principal Investigator

Investigator Affiliation:

London Health Sciences Centre


Canada: Ethics Review Committee

Study ID:

Catheter 2



Start Date:

November 2012

Completion Date:

Related Keywords:

  • Neoplasm
  • Central Venous Catheter Thrombosis
  • Neoplasms
  • Thrombosis
  • Venous Thrombosis
  • Upper Extremity Deep Vein Thrombosis